NVO — Novo Nordisk Sues Eli Lilly, Alleging Deceptive Ads For Weight-Loss Drugs

Novo Nordisk has filed a lawsuit against rival Eli Lilly, accusing it of misleading consumers with deceptive advertising for its weight-loss drugs. The complaint alleges that Lilly uses outdated clinical data to claim superior weight-loss benefits for Mounjaro and Zepbound over Novo's Ozempic and Wegovy. Novo Nordisk contends that recent studies of its own products demonstrate comparable efficacy, escalating the battle for dominance in the lucrative obesity drug market.